Literature DB >> 26874379

Variable Contribution of Heart Failure to Quality of Life in Ambulatory Heart Failure With Reduced, Better, or Preserved Ejection Fraction.

Emer Joyce1, Christine Chung1, Sabrina Badloe1, Kayode Odutayo1, Akshay Desai1, Michael M Givertz1, Anju Nohria1, Neal K Lakdawala1, Garrick C Stewart1, Michelle Young1, Joanne Weintraub1, Lynne W Stevenson1, Eldrin F Lewis2.   

Abstract

OBJECTIVES: The relative contribution of heart failure (HF) compared with other medical and nonmedical factors on diminished quality of life (QOL) across subtypes with reduced, better, and preserved left ventricular ejection fraction (LVEF) in a large ambulatory HF population was evaluated.
BACKGROUND: Dominant factors influencing limited QOL in patients with HF have not been investigated.
METHODS: Before routine HF clinic visits, 726 patients with ambulatory HF (mean age 56 ± 15 years, 37% women) completed a 1-page questionnaire that assessed QOL and relative contributions of HF compared with other medical and nonmedical factors to their QOL limitations. Visual analogue scales were used to assess overall QOL, breathing, and energy level. Results were compared across reduced (57%), preserved (16%) and better (improvement in LVEF ≥50%) (19%) subtypes.
RESULTS: Just under one-half of patients (48%) rated QOL as limited dominantly by HF, 19% rated HF and medical problems as equally limiting, 18% cited medical problems as dominant, and 15% cited nonmedical factors. Patients with HF with better LVEF had the highest overall QOL score and less dyspnea burden than those with HF with preserved EF. Independent correlates of HF-dominated diminished QOL were prior cardiac surgery, worse New York Heart Association functional class, renin-angiotensin-aldosterone antagonism, use of diuretic agents, lower body mass index, lower LVEF, and lack of arthritis or history of cancer.
CONCLUSIONS: Fewer than one-half of patients with ambulatory HF rated HF as the greatest limitation to their QOL, suggesting that this important outcome will be difficult to affect by HF-targeted therapies alone, particularly in those with higher LVEFs and comorbidities. Patients with HF with better LVEF represent a distinct subtype with better overall QOL.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  better left; heart failure; left ventricular ejection fraction; quality of life

Mesh:

Year:  2016        PMID: 26874379     DOI: 10.1016/j.jchf.2015.12.011

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN: 2213-1779            Impact factor:   12.035


  17 in total

1.  Comparing Measures to Assess Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction.

Authors:  Rebecca Napier; Steven E McNulty; David T Eton; Margaret M Redfield; Omar AbouEzzeddine; Shannon M Dunlay
Journal:  JACC Heart Fail       Date:  2018-06-06       Impact factor: 12.035

Review 2.  Epidemiology of heart failure with preserved ejection fraction.

Authors:  Shannon M Dunlay; Véronique L Roger; Margaret M Redfield
Journal:  Nat Rev Cardiol       Date:  2017-05-11       Impact factor: 32.419

3.  Diastolic dysfunction evaluated by cardiac magnetic resonance: the value of the combined assessment of atrial and ventricular function.

Authors:  Giovanni Donato Aquaro; Fausto Pizzino; Anna Terrizzi; Scipione Carerj; Bijoy K Khandheria; Gianluca Di Bella
Journal:  Eur Radiol       Date:  2018-08-20       Impact factor: 5.315

4.  Bariatric Surgery and Hospitalization for Heart Failure in Morbidly Obese Patients.

Authors:  Gursukhmandeep Singh Sidhu; Rohan Samson; Karnika Ayinapudi; Thierry H Le Jemtel
Journal:  Obes Surg       Date:  2020-07-02       Impact factor: 4.129

5.  Patients' knowledge and concerns about using the implantable cardioverter defibrillator for the primary prevention of sudden cardiac death and its correlates: A cross-sectional study.

Authors:  Mohammad A Zakeri; Nadia Sedri; Golamreza Bazmandegan; Maryam Zakeri; Mohammad Safariyan; Mahlagha Dehghan
Journal:  Health Sci Rep       Date:  2022-06-13

6.  Elderly aortic stenosis patients' perspectives on treatment goals in transcatheter aortic valvular replacement.

Authors:  Kohei Sugiura; Takashi Kohno; Kentaro Hayashida; Daisuke Fujisawa; Hiroki Kitakata; Naomi Nakano; Tetsuya Saito; Hiromu Hase; Nobuhiro Yoshijima; Hikaru Tsuruta; Yuji Itabashi; Shun Kohsaka; Keiichi Fukuda
Journal:  ESC Heart Fail       Date:  2022-06-08

Review 7.  Domain Management Approach to Heart Failure in the Geriatric Patient: Present and Future.

Authors:  Eiran Z Gorodeski; Parag Goyal; Scott L Hummel; Ashok Krishnaswami; Sarah J Goodlin; Linda L Hart; Daniel E Forman; Nanette K Wenger; James N Kirkpatrick; Karen P Alexander
Journal:  J Am Coll Cardiol       Date:  2018-05-01       Impact factor: 24.094

8.  Comorbid Conditions and Health-Related Quality of Life in Ambulatory Heart Failure Patients: REVIVAL (Registry Evaluation of Vital Information for VADs in Ambulatory Life REVIVAL).

Authors:  Thomas M Cascino; Michelle M Kittleson; Anuradha Lala; Josef Stehlik; Maryse Palardy; Salpy V Pamboukian; Gregory A Ewald; Maria M Mountis; Douglas A Horstmanshof; Shawn W Robinson; Palak Shah; Ulrich P Jorde; Rhondalyn C McLean; Blair Richards; Shokoufeh Khalatbari; Cathie Spino; Wendy C Taddei-Peters; Kathleen L Grady; Douglas L Mann; Lynne W Stevenson; Garrick C Stewart; Keith D Aaronson
Journal:  Circ Heart Fail       Date:  2020-05-18       Impact factor: 8.790

9.  Testing of a health-related quality of life model in patients with heart failure: A cross-sectional, correlational study.

Authors:  Seongkum Heo; Terry A Lennie; Debra K Moser; Sandra B Dunbar; Susan J Pressler; JinShil Kim
Journal:  Geriatr Nurs       Date:  2022-01-29       Impact factor: 2.361

10.  Comorbidity health pathways in heart failure patients: A sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry.

Authors:  Claire A Lawson; Ivonne Solis-Trapala; Ulf Dahlstrom; Mamas Mamas; Tiny Jaarsma; Umesh T Kadam; Anna Stromberg
Journal:  PLoS Med       Date:  2018-03-27       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.